NASDAQ:VCYTVeracyte Stock Price, Forecast & News

Veracyte's stock was trading at $23.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VCYT stock has increased by 43.8% and is now trading at $33.86.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Veracyte.

Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Veracyte.

Veracyte Inc (NASDAQ:VCYT) released its earnings results on Thursday, July, 30th. The biotechnology company reported ($0.22) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.22). The biotechnology company earned $20.70 million during the quarter, compared to analyst estimates of $17.56 million. Veracyte had a negative return on equity of 13.35% and a negative net margin of 27.49%.
View Veracyte's earnings history.

3 equities research analysts have issued 1-year target prices for Veracyte's stock. Their forecasts range from $37.00 to $40.00. On average, they anticipate Veracyte's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 12.2% from the stock's current price.
View analysts' price targets for Veracyte.

News headlines about VCYT stock have been trending negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Veracyte earned a coverage optimism score of -2.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Veracyte.

Veracyte saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,610,000 shares, an increase of 42.7% from the December 31st total of 2,530,000 shares. Based on an average daily volume of 498,600 shares, the short-interest ratio is presently 7.2 days. Approximately 7.7% of the shares of the company are sold short.
View Veracyte's Short Interest.

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), CareDx (CDNA), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), ALX Oncology (RNLX), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Biocept (BIOC), Enzo Biochem (ENZ) and Anpac Bio-Medical Science (ANPC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), AbbVie (ABBV), CA (CA), InVitae (NVTA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Editas Medicine (EDIT), Exelixis (EXEL) and Gilead Sciences (GILD).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte's stock is owned by a number of retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (8.50%), Sumitomo Mitsui Trust Holdings Inc. (6.28%), GW&K Investment Management LLC (2.35%), New York State Common Retirement Fund (1.67%), Bank of New York Mellon Corp (1.36%) and Granite Investment Partners LLC (1.36%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy and Robert S Epstein.
View institutional ownership trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., UBS Group AG, GW&K Investment Management LLC, Essex Investment Management Co. LLC, Falcon Point Capital LLC, Principal Financial Group Inc., and SG Americas Securities LLC. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy, and Robert S Epstein.
View insider buying and selling activity for Veracyte.

VCYT stock was bought by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Candriam Luxembourg S.C.A., Bank of New York Mellon Corp, Rafferty Asset Management LLC, Swiss National Bank, Barclays PLC, Exchange Traded Concepts LLC, and Spearhead Capital Advisors LLC.
View insider buying and selling activity for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $33.86.

Veracyte has a market capitalization of $1.71 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe.

The official website for Veracyte is www.veracyte.com.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]